SecBot SecBot

EXEL

EXELIXIS, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000939767 Biotech & Drug Discovery
$67.59 −1.41 (−2.04%)
Nov 16 4:00 PM ET · prev $69.00
Market cap
$17.0B
Large cap
Consensus
Buy
46% Buy or better · 24 analysts
Median target
$60.00
−11% · range $41.00–78.00
1 year
+59.3%
from $42.42 · Nov 17
30 days
+8.6%
from $62.23
52-week range
$40.74–72.75
−7% from high · low Mar 3
Avg volume 20D
2.78M
shares / day
Short interest
25.59M
≈10.5% of shares · −6.3%
Days to cover
11.7
at average volume
Insider net
−$19.0M
0 buyers · 9 sellers · 12 mo
New fund stakes
2
Q2 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 2 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next FDA decision date, Dec 3, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    9 insiders sold $19.0M.

  • InstitutionsMIXED

    Q2 2026: 45 added (2 new), 46 trimmed or exited. Largest new: Bank Of Nova Scotia $22.8M, Ing Groep Nv $16.9M.

  • AnalystsBULLISH

    11 of 24 rate it Buy or better. Median target $60.00 (−11%).

  • Short sellersSTEADY

    Short interest −6.3% to 25.59M shares. 11.7 days to cover, ≈10.5% of shares.

  • TrendUPTREND

    8% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 8.

Who's buying

13F· Q2 2026
2
new positions
0
exits
$39.8M
in new stakes
FundMoveSharesValue
D. E. Shaw & Co., Inc.ADD5,551,747$302.1M
UBS Group AGADD3,167,890$172.4M
GOLDMAN SACHS GROUP INCADD2,690,489$146.4M
BANK OF AMERICA CORP /DE/ADD2,149,397$116.9M
AMERICAN CENTURY COMPANIES INCADD1,791,664$97.5M
JANE STREET GROUP, LLCADD1,402,438$76.3M
JPMORGAN CHASE & COADD1,298,907$71.1M
MILLENNIUM MANAGEMENT LLCADD1,218,706$66.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

24 analysts
Buy 46% rate it Buy or better
Strong Buy4Buy7Hold12Sell1Strong Sell0
12-month targets · 14 analysts

Price is inside the target range. Median implies −11%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Nov 5, 2026Leerink Partners
MAINTAIN
MAINTAINMarket Perform
Nov 2, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 30, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Oct 30, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Oct 30, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform

Washington

Corporate Lobbying

41 lobbying filings and 2 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$19.0M
sold · 9 insiders
DateInsiderTypeValue
Aug 10, 2026
Beckerle Mary C
Director
Aug 10, 2026
SELL$526.5K
Jun 1, 2026
WYSZOMIERSKI JACK L
Director
Jun 1, 2026
SELL$198.4K
Jun 1, 2026
Eckhardt Sue Gail
Director
Jun 1, 2026
SELL$492.0K
May 27, 2026
JOHNSON DAVID EDWARD
Director
May 27, 2026
AWARD19,133 sh
May 27, 2026
Freire Maria C
Director
May 27, 2026
AWARD8,367 sh
May 27, 2026
POSTE GEORGE
Director
May 27, 2026
AWARD8,367 sh
May 27, 2026
WYSZOMIERSKI JACK L
Director
May 27, 2026
AWARD8,367 sh
May 27, 2026
Oliver Bob
Director
May 27, 2026
AWARD8,367 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
25,593,708
shares short
-6.3%
vs prior settlement
11.7
days to cover
≈10.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 9, 2026 SEC
Farallon Capital Management disclosed a new 5%+ passive stake in Exelixis, reporting beneficial ownership of…
SC 13G · Impact 3/10
Nov 9, 2026 SEC
Farallon Capital Management filed Amendment No. 9 to its Schedule 13D on Exelixis, reporting that it ceased to be a…
SC 13D/A · Impact 5/10
Oct 29, 2026 SEC
Exelixis reported Q3 2026 total revenues of $658.7M (up 10.2% YoY) and GAAP diluted EPS of $0.85 (up 23.2% YoY)…
8-K · Impact 5/10
Oct 29, 2026 Earnings result
EXEL Q3 2026 Earnings: EPS $0.94 (+15.6% vs est)
Aug 10, 2026 Insider
Beckerle Mary C sold 9,812 shares
Director @ $53.66 ($526.5K)
Jun 30, 2026 Inst.
D. E. Shaw & · ADD
5,551,747 shares ($302.1M)
Jun 30, 2026 Inst.
UBS Group AG · ADD
3,167,890 shares ($172.4M)
Jun 1, 2026 Insider
WYSZOMIERSKI JACK L sold 3,925 shares
Director @ $50.55 ($198.4K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

16 filings · 1 bullish · 2 bearish · 13 neutral
All EXEL filing & press-release reports (16)